These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2423422)

  • 1. Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs.
    Avellone G; Mandalà V; Pinto A; Martino A; Strano A
    Haemostasis; 1986; 16 Suppl 1():55-8. PubMed ID: 2423422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of defibrotide on physical performance and hemorheologic picture in patients with peripheral arteriopathy.
    Marrapodi E; Leanza D; Giordano S; Nazzari M; Corsi C
    Clin Trials Metaanal; 1994 Apr; 29(1):21-30. PubMed ID: 10150182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of defibrotide after oral and parenteral administration in patients with peripheral obliterative arterial disease (POAD).
    Craveri A; Tornaghi G; Ranieri R; Stanzani M; Landi G; Paganardi L; Passaretti B; Gallo E
    Int Angiol; 1990; 9(4):274-7. PubMed ID: 2099963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
    Strano A; Fareed J; Sabbá C; Albano O; Allegra C; Carlizza A; Binaghi F; Fronteddu F; Del Guercio R; Arpaia MR
    Semin Thromb Hemost; 1991; 17 Suppl 2():228-34. PubMed ID: 1948094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic enhancement in diabetic microangiopathy with defibrotide.
    Belcaro G; Marelli C; Pomante P; Laurora G; Cesarone MR; Ricci A; Girardello R; Barsotti A
    Angiology; 1992 Oct; 43(10):793-800. PubMed ID: 1476266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral and intravenous defibrotide on blood viscosity in patients with peripheral obliterative arterial disease.
    Belfiglio A; Traietti P; Bologna E; Salvo G
    Clin Ther; 1989; 11(4):479-84. PubMed ID: 2776165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defibrotide therapy for thrombophlebitis--controlled clinical trial.
    Di Perri T; Vittoria A; Messa GL; Cappelli R
    Haemostasis; 1986; 16 Suppl 1():42-7. PubMed ID: 3754835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of tissue plasminogen activator inhibitor by defibrotide in atherosclerotic patients.
    Violi F; Ferro D; Alessandri C; Quintarelli C; Saliola M; Balsano F
    Semin Thromb Hemost; 1989 Apr; 15(2):226-9. PubMed ID: 2501872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defibrotide and peripheral obliterative arterial disease: preliminary data.
    Arosio E; Pancera P; Zannoni M; Arcaro G; Priante F; Lechi A
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):526-9. PubMed ID: 2533180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
    Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of vascular prostacyclin and inhibition of platelet function by oral defibrotide in cholesterol-fed rabbits.
    Löbel P; Schrör K
    Atherosclerosis; 1989 Nov; 80(1):69-79. PubMed ID: 2513813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot evaluation of the effect of defibrotide in patients affected by peripheral arterial occlusive disease.
    Sabbá C; Zupo V; Dina F; Nazzari M; Albano O
    Int J Clin Pharmacol Ther Toxicol; 1988 May; 26(5):249-52. PubMed ID: 3045026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of defibrotide in the treatment of acute myocardial infarction.
    Milazzotto F; Carelli M; Citone C; Di Marcotullio G; Giampaolo P; Malinconico U; Polizzi C; Tubaro M; Giovannini E; Boccardi L
    Semin Thromb Hemost; 1989 Oct; 15(4):464-9. PubMed ID: 2814516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of defibrotide in vaso-occlusive disorders and its mode of actions.
    Ulutin ON
    Semin Thromb Hemost; 1988; 14 Suppl():58-63. PubMed ID: 2848323
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical experience in patients with chronic peripheral obliterating arteriopathy: defibrotide versus definite molecular weight heparan sulfate (MW 7500-15000 dalton)].
    Michelini S; Micci A; Failla A; Grechi G; Iantaffi A
    Minerva Cardioangiol; 1996; 44(1-2):33-7. PubMed ID: 8767620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of defibrotide on peripheral obliterative vascular diseases.
    Ulutin ON; Ilhan-Berkel N; Tunali H; Ozer M; Balkuv-Ulutin S; Onsel C; Urgancioğlu I
    Haemostasis; 1986; 16 Suppl 1():59-62. PubMed ID: 3754837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of vazaprostan in the treatment of multifocal peripheral obliterating lesions of arteries of the lower limbs].
    Driuk NF; Mishalov VG; Pavlichenko LN
    Klin Khir (1962); 1994; (10):26-8. PubMed ID: 7602901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Angioprotective activity of mexicor in atherosclerosis obliterans of the lower limbs].
    Inchina VI; Smirnov LD; Romanov MD; Kokoreva EV; Morozov MIu
    Angiol Sosud Khir; 2007; 13(3):17-20. PubMed ID: 18382390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of vasoprostan in the treatment of obliterating atherosclerosis of the lower limbs].
    Sukharev II; Guch AA
    Klin Khir (1962); 1994; (7):22-4. PubMed ID: 7823491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.